Pediatric Dermatology

A phase 3 trial studied the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis in teens.

In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).

Twyneo, a tretinoin and benzoyl peroxide cream, has been approved by the FDA for the treatment of acne vulgaris in patients 9 years and older.

Camp Wonder, a camp that supports kids with skin disease and is sponsored by Galderma, is celebrating their 20th year of operations this week.

New and forthcoming options bring opportunity for optimizing patient care.

Hair regrowth was observed after starting dupilumab treatment in some pediatric patients with a history of severe and refractory alopecia areata (AA) and concomitant atopic dermatitis (AD).

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

More than 90% of respondents to a recent survey expressed concern about acne’s effect on their adolescent’s mental health and social life.

Secukinumab (Cosentyx, Novartis) has received FDA approval for the treatment of children and adolescents with moderate to severe plaque psoriasis.

In the final part of our interview with Hilary Baldwin, MD, she details her own personal account of how she handled her daughters' acne and her advice to other dermatologists who are also parents.

In part 2 of our exclusive video interview with Hilary Baldwin, MD, she discusses new treatments for acne and how to ensure compliance of these treatments among your young patients.

In part 1 of this video interview, Hilary Baldwin, MD, explains her findings from a recently conducted survey investigating the effects of acne on both teenagers and their parents.

According to objective and subjective measures, children with more severe atopic dermatitis were more likely to report a learning disability.

Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.

An investigation examines which infants might require screening before peanut introduction.

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

With up to 30% of pediatric health care visits involving skin complaints and fewer than 400 board-certified pediatric dermatologists in the United States, teledermatology offers a valuable tool for increasing access and cutting wait times.

Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.

While Mohs micrographic surgery is well established as a safe and effective therapeutic modality in adult patients, it is not as commonly used in pediatric populations. There are unique challenges to performing Mohs surgery on pediatric patients, especially with patient cooperation. Multidisciplinary planning may be needed.

Infants with eczema may require different approaches to preventing food allergies, including early introduction of peanuts to increase oral exposure to allergens before skin exposure.

In a recent phase 3 trial, dupilumab (Dupixent, Sanofi and Regeneron) demonstrated positive results in itch reduction, skin clearance and quality-of-life. Indicating the biologic as a viable treatment option for severe atopic dermatitis in younger children.

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

In the final part of our interview with Candrice Heath, M.D., she discusses some of the treatment challenges associated with treating pediatric patients with skin of color and how to overcome these obstacles.

In part two of our interview with Candrice Heath, M.D., she explains the most commonly encountered skin conditions when treating young skin of color patients.

Candrice Heath, M.D., shares her tips and tricks for treating young skin of color patients from her presentation at the 2020 Skin of Color Update.

A recent article suggests physicians should be on the lookout for various dermatologic manifestations in pediatric patients suspected of having COVID-19.

The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.

The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6<18 years in the European Union.

Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.

The Society of Pediatric Dermatology introduces a new president and executive committee for 2020-2021 during their virtual 45th Annual Meeting.